NurOwn® Phase 2 ALS Trial: ALSFRS-R Improvement is Reflected in Subscale Domains

Ralph Kern¹, Merit Cudkowicz², James Berry³, Anthony Windebank⁴, Nathan Staff⁵, Margaret Owegi⁶, Chaim Lebovits⁷. Yael Gothelf¹. Robert Brown⁸

¹R&D, Brainstorm Cell Therapeutics Ltd, ²Massachusetts General Hospital, ³Neurological Clinical Research Institute, ⁴Mayo Clinic Dept of Neuroscience Research, ⁵Mayo Clinic, ⁶University of Massachusetts Medical Center, ⁷BrainStorm Cell Therapeutics, ⁸Univ of Massachusetts Medical School

Objective:

To evaluate the contribution of the four ALSFRS-R domains to the overall ALSFRS-R efficacy outcome in the NurOwn[®] U.S. Phase 2 ALS multicenter double-blind placebo-controlled trial (NCT02017912).

Background:

MSC-NTF cells (NurOwn®) are autologous bone-marrow derived mesenchymal stem cells (MSC) induced to secrete high levels of neurotrophic factors (NTFs). MSC-NTF cells were evaluated for safety and efficacy.

Design/Methods:

48 ALS participants were randomized 3:1 (active: placebo) and followed for 6-months posttransplantation. Responder analyses compared the treated to placebo groups in the following outcomes: ≥1.5 points/month improvement in ALSFRS-R total score; and ≥0.375 points/month (25% of 1.5) improvements in each of the four subscales measuring the bulbar, gross motor, breathing, and fine motor domains.

Results:

The trial met its primary safety endpoint. A higher percentage of study participants achieved ≥1.5 points/month improvement in the treated group at all time points, was significantly higher in the treated group at 4-weeks (onesided, p=0.02) and 12-weeks (one-sided, p=0.08), and was more evident in the subgroup that excluded slow progressors (pre-treatment change ALSFRS-R \geq -2).

The percentage of responders (≥0.375 points/month improvement) in the ALSFRS-R bulbar domain (excluding slow progressors) was significantly higher in the treated group at 4-weeks (47% vs 0, one-sided, p=0.08), 8weeks (47% vs 0, p=0.08), 12-week (40% vs 0, p=0.09), 16-weeks (47% vs 0, one-sided, p=0.06), and 24-weeks (40% vs 0, one-sided, p=0.09).

The percentage of responders (≥0.375 points/month improvement) in the ALSFRS-R fine motor domain (excluding slow progressors) was significantly higher in the treated group at 2-weeks (87% vs 40%, one-sided, p=0.07).

A higher number of participants in the treated group demonstrated ≥ 0.375 points/month improvement in gross motor and breathing domains, although these did not reach statistical significance.

Conclusions:

The observed improvements following MSC-NTF transplantation are reflected in all four ALSFRS-R domains, particularly in the bulbar and fine motor subscales.